An American buying a home in France can be refused mortgage insurance, offered coverage with a medical premium surcharge, or offered a policy that excludes the very risk that worries the lender. That result is not necessarily the end of the purchase. French law and the Convention AERAS create a route for borrowers whose health history makes ordinary underwriting difficult, but the route has limits: AERAS is not an insurer, it does not guarantee a policy, and it does not replace the bank’s separate review of foreign income, assets, and repayment capacity. The best strategy is to start the insurance search before signing a French preliminary sales contract, understand exactly what the bank requires, preserve every version of the medical questionnaire, and build a controlled evidence package for the insurer’s medical service.
This guide explains the French system for an American reader who has no French legal background. It distinguishes the no-questionnaire rule, the right to be forgotten for certain past illnesses, and the broader AERAS review for an aggravated health risk. It also explains what a refusal letter should contain, how an outside policy can replace the bank’s group policy, how to use a written complaint or AERAS mediation, and which alternative collateral may keep a transaction alive. The starting point for the wider purchase process is the firm’s French property legal checklist for American buyers.
I. Can an American with a medical condition obtain French mortgage insurance?
A. What do AERAS, the medical questionnaire, and the right to be forgotten actually cover?
French mortgage insurance is called assurance emprunteur. It is borrower insurance attached to a credit. Depending on the policy, it can pay all or part of the outstanding loan or scheduled payments if the borrower dies, suffers total and irreversible loss of autonomy, becomes permanently disabled, or is temporarily unable to work. The bank normally sets the minimum guarantees that must be present before it issues a loan offer. The insurance protects the lender’s repayment position, but it also protects a family from having to carry a French property debt after a serious event.
A French home loan is a prêt immobilier. The bank may offer its own group policy, usually negotiated for a broad pool of borrowers, or accept a policy from another insurer. The fact that a buyer is a U.S. citizen does not remove the French rules governing a French loan secured by French property. At the same time, a bank may still evaluate the American applicant’s creditworthiness separately. AERAS can improve the search for insurance; it cannot force a bank to approve a loan when the bank is not satisfied with income, assets, debt service, the property, or the source of funds.
The statutory foundation is Article L1141-2 of the French Public Health Code. It creates a national convention for people whose illness or disability creates an aggravated health risk in access to credit. The text says: « Toute personne présentant, du fait de son état de santé ou de son handicap, un risque aggravé bénéficie de plein droit de cette convention. » In practical English, a borrower who presents a higher-than-average risk of disability or death is entitled to have the AERAS framework applied. That entitlement is a right to the framework, not an unconditional right to insurance.
Convention AERAS means S’Assurer et Emprunter avec un Risque Aggravé de Santé, or “Insure and Borrow with an Aggravated Health Risk.” It is a convention among public authorities, banks, insurers, reinsurers, and patient organizations. It is not a product called “AERAS insurance.” The official Service-Public explanation of AERAS for a French mortgage expressly warns that the convention applies automatically when the health history creates an aggravated risk, but does not oblige the insurer to make an offer.
Three different protections are often confused by American applicants.
- No medical questionnaire. Under Article L113-2-1 of the Insurance Code, no health information or medical examination may be requested for the covered residential-credit situation when the insured share of the borrower’s cumulative credit does not exceed €200,000 per insured person and the credit is fully repaid before that borrower’s sixtieth birthday. The text provides that « aucune information relative à l’état de santé ni aucun examen médical de l’assuré ne peut être sollicité ». The two conditions are cumulative. A €200,000 loan that ends after the borrower turns 60 does not qualify.
- The right to be forgotten. This is the French droit à l’oubli. It allows a person who had an eligible cancer or viral hepatitis C to avoid declaring that past illness when the therapeutic protocol ended at least five years before the application, there has been no relapse, and the insurance ends before the borrower’s seventy-first birthday. This is not a general right to omit any old diagnosis. Consequences that remain, such as a current disability, work incapacity, or treatment for another condition, still have to be answered if the questionnaire asks about them.
- The AERAS reference grid. The grille de référence is a published list of conditions and waiting periods. Some conditions can lead to standard pricing or no exclusion after the relevant period; other conditions may receive a capped surcharge or limited coverage. The statutory rule appears in Article L1141-5 of the Public Health Code, which provides that « Cette grille de référence est rendue publique. » The grid changes with medical knowledge, so an American should check the version applicable when the application is filed rather than relying on an old blog post or a U.S. insurance rule.
The five-year right to be forgotten is narrower than many applicants assume. It covers the eligible past cancer or hepatitis C itself; it does not erase every question about current health. For example, a former cancer patient who now has a separate cardiac condition, an active medication, or a current work restriction must answer those questions accurately. The official Service-Public guide to obtaining French mortgage insurance makes the same distinction: when the right to be forgotten applies, the past condition need not be declared, but the consequences of the illness still must be declared.
The age and amount limits matter for an American because a long French retirement plan can push the final payment beyond age 60 or 71 even when the applicant is relatively young today. The AERAS reference-grid route generally concerns an insured credit not exceeding €420,000, excluding a bridge loan in the specified principal-residence situation, with the insurance ending before age 71. The limit concerns the insured amount and the structure of the credit, not merely the purchase price. A co-borrower’s share, a prior loan already insured by the same insurer, and a bridge loan can change the calculation.
The framework also protects confidentiality. A bank advisor is not the same person as the insurer’s medical service. An American should ask where the health questionnaire must be sent and should not casually email detailed diagnoses to a sales contact who does not need them. The official Service-Public information on health questions for death insurance confirms that the questionnaire is used to evaluate the risk and that questions may address current or past medical events. The medical evidence should travel through the channel identified by the insurer, with a copy retained by the applicant.
A refusal, a surcharge, and an exclusion are legally and commercially different outcomes. A refusal means the proposed insurer will not cover the requested risk on the submitted terms. A surcharge means the insurer accepts the risk but prices it above the ordinary rate. An exclusion means a defined event or condition is taken out of the coverage. For example, a policy might cover death but exclude incapacity connected to a particular condition. An American should compare the effect on the bank’s required guarantees, not only the monthly price.
The AERAS examination normally moves through up to three levels. Level one is the ordinary underwriting review. If the health history cannot be accepted on standard terms, the file can be considered at level two with a more individualized review and additional medical records or examinations. The most complex eligible files can reach level three, a pool of reinsurers. The official AERAS explanation reproduced by Service Public describes these successive levels and confirms that a proposal can still include a surcharge or an exclusion. A level-three review is not a promise of approval; it is a final structured attempt to find insurable terms within the convention.
For the American buyer, one practical point is decisive: foreign residence and foreign medical records do not automatically defeat an application, but they create a proof problem. The underwriter must understand the diagnosis, dates, treatment, recovery, recurrence risk, medication, and current limitations. A short U.S. medical record can be less useful than a chronological physician letter that translates those facts into the questions asked by the French questionnaire. The aim is not to give the insurer every document in existence. The aim is to provide a complete, consistent, and readable answer to each material question.
B. What evidence must an American prepare before applying?
Start before the French property search becomes contractually urgent. A compromis de vente is a French preliminary sales contract. It usually interacts with a financing timetable, a loan condition, a deposit, and deadlines for producing evidence of financing. The purchase agreement should not be signed on the assumption that mortgage insurance can be solved later in a few days. A medical review can require records from several U.S. providers, a new examination, a translation question, and a second underwriting opinion. Researching insurance before the contract gives the buyer more room to change insurers or adjust the financing.
Ask the bank for its written insurance requirements before the application is complete. The requirements should identify the guarantees, the percentage of the loan to be insured for each borrower, the definition of disability or incapacity, any maximum age, and any waiting or exclusion provisions that matter to the bank. Article L313-24 of the Consumer Code governs the French loan offer, while the Service-Public guide explains the role of the standardized information sheet and the personalized sheet. Keep those sheets. They are the benchmark against which an outside policy will be compared.
Build a medical evidence file in a fixed order. A useful package normally contains:
- a signed chronology identifying the diagnosis date, treatment dates, end of the therapeutic protocol, and any relapse or absence of relapse;
- the treating physician’s current summary, including the present condition, medication, follow-up schedule, and functional limitations;
- discharge summaries, pathology or imaging reports, operative reports, and treatment completion records that answer the insurer’s specific questions;
- records of any work interruption, disability determination, or accommodation that could be relevant to an incapacity guarantee;
- a list of current prescriptions and the dates of material changes;
- the exact French questionnaire that was completed, with a dated copy of every answer and attachment; and
- proof of identity, age, loan amount, term, and insured share so the insurer can determine whether the no-questionnaire, right-to-be-forgotten, or reference-grid conditions apply.
Do not assume that an American diagnosis maps perfectly onto a French label. Ask the physician to describe objective facts rather than using a conclusory sentence such as “cleared for insurance.” The medical service may need to know whether “remission” means the end of the treatment protocol, whether a surveillance appointment remains, and whether a medication is preventive or evidence of an active condition. If the insurer asks for a French translation, ask whether it accepts a professional translation, an English-language physician letter, or a bilingual form. The legal risk lies in an incomplete or inconsistent answer, not in the use of U.S. medical vocabulary itself.
Medical confidentiality also changes the way the file should be sent. A bank may need the result of underwriting, the premium, the exclusions, and the guarantee level. It ordinarily does not need a full pathology report. Send detailed documents to the medical service or the secure portal specified by the insurer. Use a cover page that lists each document, its date, and the question it answers. This makes it easier to prove that the insurer received the information and reduces the risk that a critical page is separated from the application.
When the questionnaire is required, answer the question actually asked. Article L113-2 of the Insurance Code states that the insured must « De répondre exactement aux questions posées par l’assureur ». That wording matters. It does not authorize an applicant to volunteer every remote health event, but it does require a precise answer to a clear question. Read time periods carefully. A question about a treatment in the last ten years is different from a question about any treatment in the applicant’s lifetime. Save the completed form before submitting it.
The sanction for an intentional false declaration is serious. Article L113-8 of the Insurance Code states that « le contrat d’assurance est nul en cas de réticence ou de fausse déclaration intentionnelle ». In practical terms, an insurer may seek nullity when a deliberate omission or false answer changes its assessment of the risk. A mistake is not automatically intentional fraud, but an American should never rely on the hope that a future claim will be the first time the insurer reviews the record.
Two Cour de cassation decisions show why the exact form and the evidence matter. In Cass. 2e civ., March 29, 2012, appeal no. 11-17.057, ECLI:FR:CCASS:2012:C200504, the dispute involved mortgage borrowers, health questionnaires, and allegations that the forms did not accurately reflect the answers. The published decision recalls the duty « de répondre exactement aux questions posées par l’assureur » and demonstrates that the authenticity, completion, and provenance of a questionnaire can become central evidence.
In Cass. 2e civ., December 12, 2013, appeal no. 12-28.829, the published decision discusses a death guarantee, a medical questionnaire, and the consequences attributed to unanswered or inaccurate health information. The decision reproduces the reasoning that « l’assuré n’a pas à rechercher dans ses réponses si le traitement médical qu’il suit est mineur ou non ». The practical lesson is not that every omission voids a policy. It is that an applicant must read a clear medical question as written and should not privately decide that a treatment is too minor to mention when the question covers it.
The opposite evidentiary caution appears in Cass. 2e civ., November 13, 2014, appeal no. 13-27.741. The published text states that the court of appeal could conclude that « Mme X…n’avait pas fait intentionnellement de fausses déclarations ». This case is fact-specific, but it illustrates why an insurer’s suspicion is not the same thing as proof of an intentional false declaration. Keep the original questionnaire, the submission emails, the medical correspondence, and the timeline. Those records allow a lawyer to test whether the wording, answer, and evidence support the refusal.
Use the AERAS reference grid as an underwriting tool, not as a slogan. Identify the exact condition, the date from which the waiting period runs, the required treatment or stabilization, the no-relapse requirement, and the maximum loan and age conditions. If the past illness is an eligible cancer or viral hepatitis C and the five-year conditions are met, ask the medical service to apply the right to be forgotten rather than placing the old diagnosis into the questionnaire. If it is another condition, disclose it when asked and request review under the current grid if the condition appears there.
Also ask whether the application falls within the €200,000 and age-60 no-questionnaire rule. It is often overlooked when two people borrow together. The limit is per insured person, but the insured share and cumulative credits must be calculated correctly. A borrower who has an existing French loan, a U.S. loan, or a second French transaction should ask the insurer to confirm the calculation in writing. If the rule applies, the insurer cannot ask for health information or an examination in the covered situation. If it does not apply, the ordinary questionnaire and AERAS review remain available.
Finally, request several quotes before committing to one underwriting channel. Insurers may assess the same medical history differently because their underwriting rules, reinsurance arrangements, guarantee definitions, and experience with cross-border applicants differ. A quote should identify the insurer, the guarantees, the insured share, the premium, the exclusions, the effective date, and the validity period. A cheaper policy that fails the bank’s personalized criteria is not a workable substitute. A more expensive policy with the required guarantees may preserve the purchase while a challenge or second review continues.
II. What can an American do after a French insurance refusal?
A. Can a delegated insurance policy or a new application overcome the refusal?
First determine who refused what. The insurer may have refused the health risk, offered a surcharge, or excluded a guarantee. Separately, the bank may have refused an outside policy because it says that the guarantees are not equivalent. Those are different decisions with different legal tools. A letter from a bank saying “insurance refused” may conceal a medical insurer’s decision, a missing document, a guarantee mismatch, or a credit decision. Ask for the complete written position and the identity of the decision-maker.
An outside policy is a délégation d’assurance, meaning that the borrower selects an insurer other than the bank’s group insurer. Article L313-30 of the Consumer Code protects that choice before the borrower signs the loan offer. The lender cannot reject another policy when it offers an equivalent level of guarantee. The article also states: « Toute décision de refus est explicite et comporte l’intégralité des motifs de refus. » The bank must identify the reasons for rejecting the substitute and, where relevant, the information or guarantees that are missing.
Do not treat “equivalent” as meaning “same insurer” or “same premium.” The bank compares the contract’s guarantee definitions, waiting periods, exclusions, covered occupations, disability threshold, method of assessing incapacity, geographic scope, and insured percentage. A U.S.-style policy may appear comprehensive but use a definition that does not match the French lender’s personalized criteria. Ask the bank to identify the precise criterion that is not satisfied, then ask the new insurer whether it can amend the policy. The amendment should be reviewed in writing before the original policy is rejected.
If the loan offer has already been issued, the bank must decide the substitution request within the statutory period. Article L313-31 of the Consumer Code refers to a decision « dans un délai de dix jours ouvrés ». It also provides for an amendment to the credit agreement when the substitute policy is accepted and prohibits extra fees for that amendment. The ten-business-day period is not a promise that the medical insurer will approve the risk in ten days; it governs the lender’s response after it receives a complete substitution request and policy information.
The lender cannot punish the borrower for choosing a compliant outside policy. Article L313-32 of the Consumer Code prevents the lender from changing the interest rate or the credit conditions, or from charging extra fees, because it accepts another insurance contract. The text includes the words « ni exiger le paiement de frais supplémentaires ». Preserve the submission date, the policy schedule, the guarantee comparison, and the bank’s response. A silent conversation with a loan officer is difficult to challenge; a dated file is not.
If the first insurer’s refusal concerns a medical condition, send a new application to another insurer rather than simply resubmitting the same file without explanation. Ask the second insurer to evaluate the application under AERAS and to state the stage reached. AERAS is applied across the relevant banking and insurance networks, but insurers do not have identical underwriting approaches. A second review can therefore produce a surcharge, a narrower exclusion, or a full offer even when the first result was a refusal. The request should explain that the applicant is seeking a fresh underwriting decision, not trying to conceal the first one.
Ask the first insurer’s medical service for the medical reasons for the refusal. The AERAS process is not designed to make an applicant guess whether the difficulty came from age, amount, duration, recurrence risk, a current treatment, a missing document, or the requested guarantee. The official Service-Public AERAS page states that the applicant can ask the insurer’s doctor in writing for the medical reasons and that the refusal should indicate the level at which it occurred. A request for reasons should be factual, dated, and limited to the application. It should not disclose unnecessary medical information to the bank’s commercial department.
When the refusal is actually a bank rejection of the substitute policy, use the written-reasons rule under Article L313-30. When it is an insurer’s medical underwriting refusal, ask for the AERAS level and medical explanation, then compare the policy with another insurer. The legal remedies are not interchangeable. An equivalent-guarantee argument cannot force an insurer to accept a medical risk that it has declined. Conversely, a bank cannot use the insurer’s medical refusal as a reason to hide why it rejected an equivalent outside policy.
An existing borrower is not locked into the original group policy. Article L113-12-2 of the Insurance Code provides that, for the covered credit insurance, « l’assuré peut résilier le contrat à tout moment » from the signing of the loan offer, subject to the substitution process and notice rules. A new policy must be accepted by the lender before the old policy is ended. The old cover should remain in place until the replacement is effective. This option can help an American who became a French resident later, whose health status has stabilized, or who can now produce a more complete medical record.
Review the “TAEA” as well as the monthly premium. TAEA is the French annual effective insurance rate: a measure used to express the insurance cost in the credit context. Compare the total cost over the loan period, the premium basis, whether the premium is calculated on original or remaining capital, the coverage percentage for each co-borrower, and the financial effect of an exclusion. The apparently cheaper quote can leave a surviving spouse exposed to a large balance. The bank’s required guarantee and the family’s risk objective should drive the comparison.
If a policy is offered with a surcharge, ask whether the AERAS cap or reduction mechanism for eligible modest-income borrowers applies. If the policy is offered with an exclusion, ask whether the exclusion is limited to one condition, one guarantee, one period, or all incapacity and disability coverage. If the proposal is conditional on an additional examination, comply only through the medical service and ask for the deadline. A proposal can expire while the buyer is waiting for the notary or the bank, so record the offer’s validity date.
Do not allow a mortgage application to become a series of informal conversations. A useful written request to the bank or insurer should state the loan amount, the term, the borrower’s age at final payment, the insured share, the requested guarantees, the date of the first application, the exact refusal or proposal, and the action requested. Attach only the documents relevant to that action. A concise request is easier to route to the medical service, AERAS contact, complaint department, or lender underwriting team.
B. How can an American challenge the decision or protect the purchase?
The first challenge is procedural. Ask for the written refusal, the AERAS level, the guarantee concerned, the medical reason through the medical service, and the documents said to be missing. Compare the decision with the questionnaire and the personalized sheet. If the insurer ignored an eligible right to be forgotten, applied an outdated grid, failed to transmit the application to the next AERAS level, or treated a non-medical administrative issue as a medical refusal, identify that error in a dated letter. State the correction requested and include proof of delivery.
The second challenge is a fresh submission. If the records were incomplete, submit the missing physician summary or treatment-completion certificate. If an American insurer’s report uses unfamiliar terminology, request a clear explanation from the treating physician. If the applicant was evaluated for the wrong guarantee or the wrong insured amount, correct the application. A fresh submission should not change facts to obtain a better answer. It should correct the record and ask the insurer to reassess the actual risk.
The third route is AERAS mediation when the convention itself was not properly applied. The mediation commission can examine an individual complaint about the convention’s application. It is not a court that sets a premium, and it does not create an automatic right to a policy. A complaint should therefore be specific: identify the loan, the date, the insurer, the stage of review, the condition or right involved, the documents sent, the response received, and the remedy sought. Attach the refusal and the correspondence. Avoid sending a full medical history unless the commission’s process asks for it through a secure channel.
The legal framework for information, instruction, and mediation is also set out in Article L1141-2-1 of the Public Health Code. It refers to the conditions of age, purpose, amount, and duration of loans, medical confidentiality, the procedure for examining applications, information about the reasons for insurance refusals, and a mediation mechanism. These details matter to an American because an application can be eligible in principle but outside the amount or age limits for a particular AERAS escalation.
Use the purchase contract’s financing language immediately. If a French preliminary sales contract contains a financing condition, a refusal of credit or insurance may affect the buyer’s ability to complete the purchase, but the result depends on the contract’s wording, the amount and term sought, the deadlines, and the evidence of a genuine application. Do not simply miss a deadline. Send the refusal to the notary, request a written extension if needed, and have a French lawyer review whether the application matched the contract’s financing terms. A timely insurance refusal can be useful evidence; an undocumented delay may create a different dispute.
When insurance is not available, ask the lender about alternative collateral. A caution is a guarantor who undertakes to pay the bank if the borrower defaults. A nantissement is a pledge of an asset, such as a life-insurance contract or securities portfolio, that gives the bank rights over the pledged value. An hypothèque is a mortgage over real property. The bank evaluates the value, liquidity, ranking, and enforceability of the proposed security. It may accept another French property, a cash deposit, a pledge of eligible investments, or a different co-borrower structure, but it is not required to accept every proposal.
A guarantee alternative changes the negotiation rather than erasing the health refusal. The bank still assesses repayment capacity and the value of the collateral. An American should obtain the lender’s written list of accepted alternatives, the valuation method, the required margin, the costs, and the release conditions. A pledge of a U.S. account may be harder to enforce than a French asset, and a U.S. life-insurance policy may not be accepted in the same way as a French contract. The fact that an asset exists is not enough; the bank needs a security it can legally and practically use.
Cross-border tax rules do not decide whether a medical risk is insurable. The France–U.S. income and wealth tax treaty is a tax-allocation instrument, not an underwriting code. The consolidated treaty text is available from the French tax administration. FATCA is an information-reporting framework, described in the French tax administration’s FATCA guidance. Neither document gives a lender a reason to ignore the French equivalence rules, and neither creates a right to mortgage insurance. They may still affect the bank’s source-of-funds, account, and reporting questions.
That distinction is useful when a bank says that an American applicant is “too complicated.” Ask the bank to separate the medical underwriting issue from U.S. tax documentation, foreign income verification, anti-money-laundering checks, and credit policy. A W-9, Form 1040, brokerage statement, or FATCA self-certification may be relevant to the bank’s compliance process. None substitutes for the insurer’s medical decision. Conversely, a medical refusal cannot automatically justify rejecting an equivalent policy without the written reasons required by French consumer law.
If the application is already insured and a later claim is refused, the dispute shifts from underwriting to contract performance. Compare the claim refusal with the policy notice, the guarantee definition, the exclusion clause, the medical answers, and the date the risk occurred. The insurer must rely on the contract and the applicable legal rules; the borrower must prove the event and respect the claim procedure. The 2012, 2013, and 2014 Cour de cassation decisions cited above show why the original questionnaire and the proof of intent can matter years after a loan is issued.
Keep a single digital and paper file. It should contain the bank’s personalized insurance criteria, every insurance quote, the first and later questionnaires, the medical-service submission receipts, the refusal letters, the reasons request, the AERAS correspondence, the mediation submission, the compromis de vente, the financing condition, and the notary’s deadlines. Use file names with dates and never overwrite an earlier version. An American living in a different time zone should also record the time a message was sent and the French deadline it addressed.
There is no universal answer to the question “Will AERAS get me insured?” The correct answer depends on the illness, treatment history, age at final payment, insured amount, requested guarantee, current functional effects, insurer, and completeness of the file. An eligible former cancer patient may qualify for the right to be forgotten. A borrower with an ongoing chronic condition may obtain coverage through the reference grid or a tailored policy. Another applicant may need a surcharge, an exclusion, a different insurer, or alternative collateral. A refusal becomes actionable when it is converted into a precise question: which rule, guarantee, document, or fact produced the result?
Conclusion
An American with a pre-existing medical condition can often keep a French property project alive after a mortgage-insurance problem, but the sequence matters. Check first whether the €200,000 and age-60 conditions remove the medical questionnaire. If not, determine whether the right to be forgotten or the AERAS reference grid applies. Prepare a chronological, physician-supported evidence file and send it through the insurer’s medical channel. Obtain several written proposals before signing the French preliminary sales contract.
After a refusal, separate the insurer’s medical decision from the bank’s decision on an outside policy. Ask for the AERAS level and medical reasons, correct missing evidence, seek a fresh review with another insurer, and use AERAS mediation when the convention was not applied. If an outside policy meets equivalent guarantees, rely on the written-reasons, ten-business-day, and no-extra-fee protections in the Consumer Code. If insurance remains unavailable, ask the lender about a guarantor, pledge, or mortgage over another asset and protect the financing deadlines in the purchase contract.